Format

Send to

Choose Destination
Clin Cancer Res. 2012 Mar 15;18(6):1490-2. doi: 10.1158/1078-0432.CCR-11-3282. Epub 2012 Feb 8.

Two sides of the same coin: EGFR exon 19 deletions and insertions in lung cancer.

Author information

1
Yale University School of Medicine, New Haven, CT, USA. katerina.politi@yale.edu

Abstract

Most lung adenocarcinoma-associated EGF receptor (EGFR) mutations confer sensitivity to specific EGFR tyrosine kinase inhibitors. The finding that exon 19 insertion mutations are also sensitive to this class of drugs suggests that testing for these mutations should be done and that these patients will benefit from treatment with tyrosine kinase inhibitors.

PMID:
22317760
PMCID:
PMC3329215
DOI:
10.1158/1078-0432.CCR-11-3282
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center